In this article, Ash Gude shares key considerations for weighing the benefits of offshoring and nearshoring in the pharmaceutical industry. Nearshoring helps manufacturers make strategic decisions that balance cost-efficiency with the need for a stable, responsive, and compliant supply chain, ensuring the consistent availability of high-quality APIs:
He also talks about why while there are clear benefits to both offshoring and nearshoring API sourcing, companies must also carefully consider the associated risks:
The decision to offshore or nearshore API sourcing involves balancing cost, quality, and supply chain risks. Offshoring can reduce costs but adds risks like supply disruptions and regulatory challenges, while nearshoring offers more control but higher costs. The choice depends on a company’s strategy, regulatory needs, and risk tolerance. A well-informed, risk-based approach is key to ensuring a reliable supply of medications and long-term success in the pharmaceutical industry.
Read More on Pharmaceutical Online →
Ashay Gude
Director, US Consulting
Ashay Gude is a senior management consultant at TBM Consulting Group with 16 years of expertise in management consulting, operations and supply chain management, operational excellence, change management and team leadership in the United States, Japan, and Canada. He drives organizational transformation, cost reduction, and performance improvement. Gude has led a progressive career at pharmaceutical and medical solutions manufacturers such as Abbott Laboratories, Young Innovations, and Germiphene. He has bachelor’s and master’s degrees in mechanical engineering and an MBA. He is also a Lean Six Sigma Black Belt (ASQ).
Don’t miss industry expert insights.
Join a community committed to excellence.
